RxDoctor Payments Data

Alexander Mauskop, MD

Cardiovascular Disease · New York, NYNPI 1215194659

Payments from drug & device makers

$70,599in general payments, 2019–2025

Across 241 payments — averaging $292.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$32K
  • Biohaven Pharmaceutical Holding Company Ltd.$18K
  • Lundbeck LLC$17K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$640
  • Kowa Pharmaceuticals America, Inc.$229
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$5,1007%
  • Speaking & faculty fees$58,25083%
  • Travel & lodging$1,5682%
  • Food & beverage$5,6388%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,599 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$481,979
Medicare patients
861
Services billed
4,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$269,336
EliquisApixaban125$134,720
JardianceEmpagliflozin96$97,063
XareltoRivaroxaban50$49,837
OzempicSemaglutide19$39,606
MultaqDronedarone Hcl26$36,407
EntrestoSacubitril/Valsartan16$26,463
Repatha SureclickEvolocumab27$22,302
FarxigaDapagliflozin Propanediol11$11,297
Rosuvastatin Calcium304$4,642
Eplerenone46$3,017
Metoprolol Succinate152$2,874
Ezetimibe105$2,849
Nebivolol Hcl40$2,624
Losartan Potassium254$2,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$22$404,056137 claims
Boehringer IngelheimJardiance, Pradaxa$172$99,265107 claims
Johnson & JohnsonXarelto$182$49,83750 claims
Novo NordiskOzempic$132$39,60619 claims
Sanofi-aventis U.S. LLCMultaq$138$36,40726 claims
NovartisEntresto$170$26,46316 claims
AstraZenecaFarxiga$229$11,29711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →